Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annu...(9percent for placebo) and also for media...)

The pooled results among all patients in the intent-to-treat analysis, including those who dropped out during the titration period, also demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was reduced by 33.3 percent for the 200 mg/day group, 36.8 percent for the 400 mg/day group, and by 39.4 percent for the 600 mg/day group, compared with 18.4 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

-- Responder rates were 34.1 percent for 200 mg/day, 39.7 percent for 400 mg/day, and 39.6 percent for 600 mg/day, compared with 22.6 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.196)

Steve Chung, MD, David Rudd, David Hebert, PhD, Pamela Doty

Barrow Neurological Institute, Phoenix, AZ; SCHWARZ BIOSCIENCES (a member of the UCB Group), Research Triangle Park, Raleigh, North Carolina

Lacosamide Efficacy is Independent of Concomitant AED(s) Treatment

This analysis evaluated pooled data from the placebo and 400 mg/day Vimpat(R) treatment groups of each trial by the most frequently used concomitant AEDs. The most commonly used concomitant AEDs for this patient population were carbamazepine, lamotrigine, levetiracetam, valproate, and oxcarbazepine.

Overall, reduction in seizure frequency was 36.8 percent for adjunctive treatment with Vimpat(R) 400 mg/day versus 18.4 percent for adjunctive treatment with placebo. When analyzed by individual concomitant AED use, Vimpa
'/>"/>